Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive save search
Critical Elements complete Positive Engineering Study for a Lithium Hydroxide Monohydrate Plant
Published: 2022-08-11 (Crawled : 13:00) - cecorp.ca
LTUM | $0.0364 -3.96% 33.16% 230K
|
Mining, Quarrying, and Oil and ...
|
| O: 0.0%
H: 5.47%
C: 2.49%
CRECF | $0.48 -1.23% 0.15% 1.1K
|
Process Industries
|
| O: 0.0%
H: 3.05%
C: 0.78%
lithium positive study
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis
Published: 2022-08-10 (Crawled : 22:00) - biospace.com/
RANI | $6.05 -22.93% -28.48% 570K
|
|
| O: 3.82%
H: 0.79%
C: -2.76%
rt-102 topline therapeutics positive results study osteoporosis phase 1
Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension
Published: 2022-08-10 (Crawled : 13:00) - biospace.com/
LEXX | $2.25 -3.85% -4.0% 120K
|
Health Technology
|
| O: 1.79%
H: 4.23%
C: 1.06%
fda meeting hypertension positive
Talos Energy Provides Update on Additional Positive Impacts from the Inflation Reduction Act
Published: 2022-08-09 (Crawled : 11:00) - prnewswire.com
TALO | $13.28 0.08% 0.0% 980K
|
Energy Minerals
|
| O: 2.21%
H: 2.65%
C: 0.43%
energy positive update
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
Published: 2022-08-08 (Crawled : 11:00) - biospace.com/
KRTX | $329.83 0.0% 1.9M
|
Health Technology
|
| O: 57.4%
H: 10.9%
C: 9.18%
schizophrenia trial therapeutics positive results
Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion
Published: 2022-08-08 (Crawled : 11:00) - prnewswire.com
KOD | $3.47 -3.61% -3.6% 570K
|
Health Technology
|
| O: 17.86%
H: 2.7%
C: -3.22%
ksi-301 beacon sciences topline positive results study
Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs
Published: 2022-08-04 (Crawled : 17:00) - biospace.com/
PPRUF | News | $358.55 -0.93% 37.56% 1.5K
|
Consumer Non-Durables
|
| O: 0.0%
H: 5.96%
C: 2.52%
PPRUY | News | $36.0023 -0.08% -0.11% 220K
|
Manufacturing
|
| O: 0.04%
H: 1.21%
C: 0.78%
PCVX | $60.62 -2.9% -2.93% 660K
|
Health Technology
|
| O: 1.43%
H: 3.54%
C: 3.14%
STRO M | $3.77 -0.79% -1.06% 770K
|
Health Technology
|
| O: 1.68%
H: 1.28%
C: 0.55%
vax-24 positive
SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting
Published: 2022-08-04 (Crawled : 13:00) - biospace.com/
SCYX | $1.405 -1.06% 3.4% 80K
|
Health Technology
|
| O: 1.58%
H: 12.84%
C: 7.0%
meeting infections positive study
Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS
Published: 2022-08-03 (Crawled : 00:00) - biospace.com/
SYRS | $4.72 -7.63% -7.35% 120K
|
Health Technology
|
| O: 2.17%
H: 9.03%
C: 5.34%
treatment designation drug positive
Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial
Published: 2022-08-03 (Crawled : 16:00) - biospace.com/
LABP | $21.75 0.37% 0.28% 21K
|
|
| O: 23.25%
H: 0.3%
C: -5.05%
nx-13 biopharma trial positive results phase 2b
Senseonics Announces a Positive Coverage Decision for Eversense® E3 CGM from Anthem
Published: 2022-08-03 (Crawled : 12:20) - biospace.com/
SENS | $0.416 3.43% -2.64% 2.2M
|
Electronic Technology
|
| O: 6.3%
H: 24.44%
C: 23.7%
eversense positive
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Published: 2022-08-03 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
ALNY | News | $145.16 -0.11% -0.19% 400K
|
Health Technology
|
| O: 47.44%
H: 0.0%
C: 0.0%
topline positive results study
Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung Cancer
Published: 2022-08-02 (Crawled : 06:00) - biospace.com/
HALO M | $37.81 -0.55% -0.48% 550K
|
Health Technology
|
| O: 0.54%
H: 0.43%
C: -1.76%
tecentriq positive results cancer study
Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model
Published: 2022-08-01 (Crawled : 13:00) - globenewswire.com
QLGN | $0.3117 4.81% -2.2% 27K
|
Health Technology
|
| O: 11.39%
H: 2.89%
C: -11.04%
qn-247 therapeutics readout positive cancer negative
Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC
Published: 2022-08-01 (Crawled : 12:20) - globenewswire.com
IMMP | News | $2.2 -2.66% -2.73% 270K
|
Health Technology
|
| O: -1.77%
H: 1.8%
C: 1.8%
positive study
Concert Pharmaceuticals Reports Positive Topline Results for Second CTP‑543 Phase 3 Clinical Trial in Alopecia Areata
Published: 2022-08-01 (Crawled : 12:00) - biospace.com/
CNCE | $8.37 0.36% 0
|
Health Technology
|
| O: 12.57%
H: 4.0%
C: -1.83%
topline trial positive
ViiV Healthcare presents positive five-year data at AIDS 2022, demonstrating the durability of fostemsavir in people living with HIV who are heavily treatment-experienced
Published: 2022-07-29 (Crawled : 13:00) - biospace.com/
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: -0.32%
H: 0.3%
C: -0.1%
hiv positive living
Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19
Published: 2022-07-29 (Crawled : 12:00) - biospace.com/
ENTA | $13.23 -5.5% -5.82% 150K
|
Health Technology
|
| O: 0.62%
H: 10.62%
C: 10.28%
edp-235 covid-19 treatment positive study phase 1
The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
BIIB | $190.52 -0.85% -0.84% 1.3M
|
Health Technology
|
| O: -0.26%
H: 1.35%
C: 0.87%
biib059 lupus positive phase 2
Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
AGNPF | $0.0708 5.36% 178.69% 1.3K
|
Health Technology
|
| O: 0.12%
H: 1.62%
C: 1.62%
positive study phase 2
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
ZCMD | $1.45 5.84% 49.63% 15M
|
Commercial Services
TPET | $0.3279 -3.56% 28.48% 33M
|
n/a
VTNR 4 | $1.31 33.78% 25.82% 220K
|
Industrial Services
GDHG | $0.263 21.76% 25.34% 1.3M
|
HOLO | $2.95 31.7% 22.49% 37M
|
MTNB | $0.19 -1.04% 14.58% 950K
|
Health Technology
UMAC | $1.55 0.65% 12.9% 0
|
TAOP | $1.08 13.01% 11.51% 19K
|
Technology Services
MGLD 4 | $1.13 5.61% 10.62% 200
|
Manufacturing
NURO | $3.65 2.24% 10.3% 3.9K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.